There are 2789 resources available
860MO - Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
Presenter: Hye Ryun Kim
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
861MO - Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)
Presenter: Joseph Curry
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
862MO - Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
Presenter: Loris De Cecco
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
863MO - Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016
Presenter: Michael Kharouta
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study
Presenter: Paolo Bossi
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
1670MO - Validation of a new risk-assessment model for prediction of venous thromboembolism in cancer outpatients: The ONKOTEV score
Presenter: Chiara Alessandra Cella
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1443MO - Differences in hematologists’ and palliative care physicians’ recommended indications and opinions on transfusion therapy for patients with hematological malignancy post-anticancer therapy
Presenter: Yukako Hattori
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1671MO - Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Sibylle Loibl
Session: Do we need checkpoint inhibitors as part of the neoadjuvant therapy in TNBC?
Resources:
Slides
Webcast
Yes
Presenter: Jonas Bergh
Session: Do we need checkpoint inhibitors as part of the neoadjuvant therapy in TNBC?
Resources:
Slides
Webcast